MARKET

INKT

INKT

Mink Therapeutics, Inc.
NASDAQ
9.34
-0.19
-1.99%
After Hours: 9.34 0 0.00% 19:30 11/13 EST
OPEN
9.68
PREV CLOSE
9.53
HIGH
9.68
LOW
9.00
VOLUME
18.96K
TURNOVER
--
52 WEEK HIGH
16.93
52 WEEK LOW
8.48
MARKET CAP
47.66M
P/E (TTM)
-4.1517
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), MiNK Therapeutics (INKT)
TipRanks · 1d ago
MiNK Therapeutics Reports Third Quarter 2026 Results and First Pre-Commercial Product Revenue
NASDAQ · 1d ago
MiNK Therapeutics Q3 Loss Narrows; Reports First Pre-Commercial Revenue From AgenT-797
NASDAQ · 3d ago
MiNK Therapeutics, Inc. (INKT) Reports Q3 Loss, Beats Revenue Estimates
NASDAQ · 3d ago
MiNK Therapeutics Q3 2026 Earnings Call Transcript
Benzinga · 3d ago
MiNK Therapeutics reports Q3 EPS (50c), consensus (66c)
TipRanks · 3d ago
MiNK Therapeutics Q3 EPS $(0.50) Beats $(0.66) Estimate
Benzinga · 3d ago
MiNK Therapeutics GAAP EPS of -$0.50 beats by $0.16, revenue of $0.2M beats by $0.13M
Seeking Alpha · 3d ago
More
About INKT
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.

Webull offers Mink Therapeutics Inc stock information, including NASDAQ: INKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INKT stock methods without spending real money on the virtual paper trading platform.